MBX Biosciences falls after executive shakeup - MBX News | RalliesMBX Biosciences falls after executive shakeup
M
MBX• Shares fall after leadership changes
- Shares of drug developer MBX Biosciences fell 2.6% to $58.49 after the bell.
- MBX named insider Steve Hoerter as its new chief executive officer, succeeding Kent Hawryluk.
- The company also appointed John Smither, interim finance chief since March 2026, as its new chief financial officer.
- All leadership changes are effective immediately.
- MBX stock has nearly doubled so far this year.
TREX
•
